JP2008513352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008513352A5 JP2008513352A5 JP2007519460A JP2007519460A JP2008513352A5 JP 2008513352 A5 JP2008513352 A5 JP 2008513352A5 JP 2007519460 A JP2007519460 A JP 2007519460A JP 2007519460 A JP2007519460 A JP 2007519460A JP 2008513352 A5 JP2008513352 A5 JP 2008513352A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- nitrogen
- oxygen
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 64
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 38
- 229910052757 nitrogen Inorganic materials 0.000 claims 27
- 229910052760 oxygen Inorganic materials 0.000 claims 26
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 25
- 125000005842 heteroatom Chemical group 0.000 claims 25
- 239000001301 oxygen Chemical group 0.000 claims 25
- 229910052717 sulfur Inorganic materials 0.000 claims 24
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 23
- 239000011593 sulfur Chemical group 0.000 claims 23
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 18
- 229920006395 saturated elastomer Polymers 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 12
- 125000002950 monocyclic group Chemical group 0.000 claims 12
- 125000001931 aliphatic group Chemical group 0.000 claims 11
- 208000030507 AIDS Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- -1 2-phenoxyphenyl Chemical group 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 230000003463 hyperproliferative effect Effects 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 206010039083 rhinitis Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000035939 Alveolitis allergic Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 208000027445 Farmer Lung Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010024227 Lepromatous leprosy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000036284 Rhinitis seasonal Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000021388 Sezary disease Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- NINIDFKCEFEMDL-RNFDNDRNSA-N Sulfur-36 Chemical group [36S] NINIDFKCEFEMDL-RNFDNDRNSA-N 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000001118 alkylidene group Chemical group 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 1
- 201000009151 chronic rhinitis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 1
- 208000022195 farmer lung disease Diseases 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 201000009240 nasopharyngitis Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58438304P | 2004-06-30 | 2004-06-30 | |
| US60/584,383 | 2004-06-30 | ||
| US58472104P | 2004-07-01 | 2004-07-01 | |
| US60/584,721 | 2004-07-01 | ||
| US11/098,751 | 2005-04-04 | ||
| USPCT/US05/11358 | 2005-04-04 | ||
| PCT/US2005/011358 WO2005103050A2 (en) | 2004-04-02 | 2005-04-04 | Azaindoles useful as inhibitors of rock and other protein kinases |
| US11/098,751 US7514448B2 (en) | 2004-04-02 | 2005-04-04 | Azaindoles useful as inhibitors of rock and other protein kinases |
| PCT/US2005/023429 WO2006004984A1 (en) | 2004-06-30 | 2005-06-29 | Azaindoles useful as inhibitors of protein kinases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011227135A Division JP2012012417A (ja) | 2004-06-30 | 2011-10-14 | タンパク質キナーゼのインヒビターとして有用なアザインドール |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008513352A JP2008513352A (ja) | 2008-05-01 |
| JP2008513352A5 true JP2008513352A5 (enExample) | 2008-08-14 |
| JP5122280B2 JP5122280B2 (ja) | 2013-01-16 |
Family
ID=37801682
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007519460A Expired - Fee Related JP5122280B2 (ja) | 2004-06-30 | 2005-06-29 | タンパク質キナーゼのインヒビターとして有用なアザインドール |
| JP2011227135A Pending JP2012012417A (ja) | 2004-06-30 | 2011-10-14 | タンパク質キナーゼのインヒビターとして有用なアザインドール |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011227135A Pending JP2012012417A (ja) | 2004-06-30 | 2011-10-14 | タンパク質キナーゼのインヒビターとして有用なアザインドール |
Country Status (4)
| Country | Link |
|---|---|
| JP (2) | JP5122280B2 (enExample) |
| IL (1) | IL180303A0 (enExample) |
| MX (1) | MX2007000092A (enExample) |
| NO (1) | NO20070502L (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007000092A (es) * | 2004-06-30 | 2007-03-07 | Vertex Pharma | Azaindoles utiles como inhibidores de proteinas cinasas. |
| AU2005272815A1 (en) * | 2004-08-13 | 2006-02-23 | Genentech, Inc. | Thiazole based inhibitors of ATP-utilizing enzymes |
| DE102008038221A1 (de) * | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-Azaindolderivate |
| DE102009058280A1 (de) * | 2009-12-14 | 2011-06-16 | Merck Patent Gmbh | Thiazolderivate |
| DK2558446T5 (da) | 2010-04-16 | 2019-12-09 | Ac Immune Sa | Nye forbindelser til behandling af sygdomme associerede med amyloid- eller amyloidlignende proteiner |
| MX2013000103A (es) * | 2010-06-23 | 2013-06-13 | Vertex Pharma | Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art. |
| DE102011105469A1 (de) * | 2011-06-24 | 2012-12-27 | Merck Patent Gmbh | 7-Azaindolderivate |
| JP6225178B2 (ja) * | 2012-05-31 | 2017-11-01 | フェネックス ファーマシューティカルス アーゲー | オーファン核内受容体ＲＯＲγの調整剤としてのカルボキサミドまたはスルホンアミド置換されたチアゾールおよび関連する誘導体 |
| AU2015215582B2 (en) * | 2014-02-04 | 2016-10-13 | Taiho Pharmaceutical Co., Ltd. | Azaindole derivative |
| IL301740A (en) * | 2020-10-05 | 2023-05-01 | Enliven Therapeutics Inc | 7-azaindole compounds for inhibition of bcr-abl tyrosine kinases |
| WO2023110843A1 (en) * | 2021-12-15 | 2023-06-22 | Almirall, S.A. | Heterobicyclic derivatives as itk inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6265403B1 (en) * | 1999-01-20 | 2001-07-24 | Merck & Co., Inc. | Angiogenesis inhibitors |
| US7105550B2 (en) * | 2000-03-01 | 2006-09-12 | Christopher Love | 2,4-disubstituted thiazolyl derivatives |
| SE0202463D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| AU2005236002A1 (en) * | 2004-04-02 | 2005-11-03 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of rock and other protein kinases |
| MX2007000092A (es) * | 2004-06-30 | 2007-03-07 | Vertex Pharma | Azaindoles utiles como inhibidores de proteinas cinasas. |
-
2005
- 2005-06-29 MX MX2007000092A patent/MX2007000092A/es active IP Right Grant
- 2005-06-29 JP JP2007519460A patent/JP5122280B2/ja not_active Expired - Fee Related
-
2006
- 2006-12-25 IL IL180303A patent/IL180303A0/en unknown
-
2007
- 2007-01-26 NO NO20070502A patent/NO20070502L/no not_active Application Discontinuation
-
2011
- 2011-10-14 JP JP2011227135A patent/JP2012012417A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528889A5 (enExample) | ||
| JP2009506123A5 (enExample) | ||
| JP2009507792A5 (enExample) | ||
| JP2007519742A5 (enExample) | ||
| JP2003507456A5 (enExample) | ||
| JP2009536617A5 (enExample) | ||
| KR102083857B1 (ko) | 신규 치환된 인다졸, 그의 제조 방법, 상기 신규 치환된 인다졸을 함유하는 제약 제제, 및 약물을 제조하기 위한 상기 신규 치환된 인다졸의 용도 | |
| ES2461967T3 (es) | Compuestos de pirrolo[2,3-d]pirimidina | |
| US9221805B2 (en) | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | |
| AU2014233414B2 (en) | N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2017528498A5 (enExample) | ||
| JP2008513352A5 (enExample) | ||
| RU2007120518A (ru) | ПИРАЗОЛО [1,5,-a] ПИРИМИДИНЫ, ПРИМЕНЯЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОИЕИНКИНАЗ | |
| US10208059B2 (en) | Heterocyclic modulators of HIF activity for treatment of disease | |
| JP2020505395A5 (enExample) | ||
| JP2018520195A5 (enExample) | ||
| JP2019519598A5 (enExample) | ||
| JP2020505396A5 (enExample) | ||
| BR112017010354B1 (pt) | Compostos de triazolopirimidina e usos dos mesmos | |
| JP2014525427A5 (enExample) | ||
| JP2017525757A5 (enExample) | ||
| CN105085428B (zh) | 芳杂环类衍生物及其在药物上的应用 | |
| US20110288081A1 (en) | Pyrimidine compounds and uses thereof | |
| JP2017537948A (ja) | Ｎａｄｐｈオキシダーゼ阻害剤としてのアミドチアジアゾール誘導体 | |
| JP2010509375A5 (enExample) |